Pub. Date : 2017
PMID : 28408884
5 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Effect of CYP3A4*1G and CYP3A5*3 Polymorphisms on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects. | Ticagrelor | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
| 2 | Genetic differences in CYP3A4 and CYP3A5 expression in human volunteers and patients might affect the clearance of ticagrelor or AR-C124910XX in vivo resulting in subsequent variable patient response. | Ticagrelor | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
| 3 | Thus, this study is designed to explore the effects of CYP3A4*1G and CYP3A5*3 polymorphisms on the pharmacokinetics and pharmcodynamics of ticagrelor in healthy Chinese subjects. | Ticagrelor | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
| 4 | The results indicated that the CYP3A4*1G polymorphism significantly influenced the pharmacokinetics of AR-C124910XX, and it may be more important than CYP3A5*3 with respect to influencing ticagrelor pharmacokinetics by increasing CYP3A4 activity. | Ticagrelor | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
| 5 | The results indicated that the CYP3A4*1G polymorphism significantly influenced the pharmacokinetics of AR-C124910XX, and it may be more important than CYP3A5*3 with respect to influencing ticagrelor pharmacokinetics by increasing CYP3A4 activity. | Ticagrelor | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |